A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
Christopher Gibson, insider at Recursion Pharmaceuticals

Christopher Gibson Insider Information

Christopher Gibson, Ph.D., is our co-founder, Chief Executive Officer since the company’s founding in November 2013. Dr. Gibson was also Chairman of our Board from the company’s founding until he asked, with the support of the rest of the Board, for Dr. R. Martin Chavez to accept a position of Chairman in January 2021.

Previously, Dr. Gibson was an M.D./Ph.D. student at the University of Utah. After obtaining his Ph.D., he withdrew from medical school to found Recursion. He has undergraduate degrees in bioengineering (B.S.) and managerial studies (B.A.) Rice University. He has served as a Founding Chairman of the Board of BioHive (the Utah life science collective and branding effort, composed of therapeutics, diagnostics, medical device and health IT companies, along with the companies that support them and the public sector) since November 2020. He also serves as a Board member of BioUtah (the Utah life science industry association) since January 2019, Board member of the Recursion Foundation (our not-for-profit entity seeking to promote corporate social responsibility) since November 2019, through which he is on the Board of Altitude Lab (an incubator/accelerator focused on creating the next generation of diverse biotech founder in Utah) since July 2020.

Dr. Gibson has also served on the Cures Acceleration Network Review Board since September 2020. Dr. Gibson is co-author of more than a dozen peer-reviewed studies in a variety of journals including Nature, Nature Protocols, Circulation, the Journal of Clinical Investigation, Molecular Pharmaceutics, PloS One, and Diabetes. Our Board believes Dr. Gibson is qualified to serve on our Board because of his scientific and technical background and his knowledge and perspective of the Company.

What is Christopher Gibson's net worth?

The estimated net worth of Christopher Gibson is at least $7.02 million as of August 4th, 2022. Dr. Gibson owns 541,829 shares of Recursion Pharmaceuticals stock worth more than $7,022,104 as of August 15th. This net worth estimate does not reflect any other investments that Dr. Gibson may own. Additionally, Dr. Gibson receives an annual salary of $673,590.00 as CEO at Recursion Pharmaceuticals. Learn More about Christopher Gibson's net worth.

How old is Christopher Gibson?

Dr. Gibson is currently 39 years old. There are 4 older executives and no younger executives at Recursion Pharmaceuticals. The oldest executive at Recursion Pharmaceuticals is Ms. Louisa Daniels J.D., M.B.A., Chief Legal Officer & Gen. Counsel, who is 64 years old. Learn More on Christopher Gibson's age.

What is Christopher Gibson's salary?

As the CEO of Recursion Pharmaceuticals, Inc., Dr. Gibson earns $673,590.00 per year. The highest earning executive at Recursion Pharmaceuticals is Dr. Shafique Virani M.D., Interim Chief Medical Officer & Chief Bus. Officer, who commands a salary of $688,170.00 per year. Learn More on Christopher Gibson's salary.

How do I contact Christopher Gibson?

The corporate mailing address for Dr. Gibson and other Recursion Pharmaceuticals executives is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. Recursion Pharmaceuticals can also be reached via phone at 385-269-0203 and via email at [email protected] Learn More on Christopher Gibson's contact information.

Has Christopher Gibson been buying or selling shares of Recursion Pharmaceuticals?

Within the last three months, Christopher Gibson has sold $685,350.95 in Recursion Pharmaceuticals stock. Most recently, Christopher Gibson sold 36,825 shares of the business's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $9.49, for a transaction totalling $349,469.25. Following the completion of the sale, the chief executive officer now directly owns 541,829 shares of the company's stock, valued at $5,141,957.21. Learn More on Christopher Gibson's trading history.

Who are Recursion Pharmaceuticals' active insiders?

Recursion Pharmaceuticals' insider roster includes Blake Borgeson (Director), Christopher Gibson (CEO), Tina Larson (COO), and Dean Li (Director). Learn More on Recursion Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Recursion Pharmaceuticals?

In the last year, insiders at the sold shares 27 times. They sold a total of 1,256,106 shares worth more than $10,550,959.98. The most recent insider tranaction occured on August, 4th when CEO Christopher Gibson sold 36,825 shares worth more than $349,469.25. Insiders at Recursion Pharmaceuticals own 22.3 % of the company. Learn More about insider trades at Recursion Pharmaceuticals.

Information on this page was last updated on 8/4/2022.

Christopher Gibson Insider Trading History at Recursion Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/4/2022Sell36,825$9.49$349,469.25541,829View SEC Filing Icon  
7/7/2022Sell37,114$9.05$335,881.70528,904View SEC Filing Icon  
6/2/2022Sell39,690$6.09$241,712.10516,268View SEC Filing Icon  
5/4/2022Sell31,830$6.49$206,576.70511,972View SEC Filing Icon  
4/28/2022Sell37,605$6.09$229,014.45469,608View SEC Filing Icon  
4/21/2022Sell37,155$6.31$234,448.05420,146View SEC Filing Icon  
4/18/2022Sell35,836$6.84$245,118.24394,791View SEC Filing Icon  
4/14/2022Sell34,517$7.56$260,948.52368,117View SEC Filing Icon  
4/7/2022Sell36,718$6.54$240,135.72314,534View SEC Filing Icon  
4/5/2022Sell34,472$7.43$256,126.96288,742View SEC Filing Icon  
3/14/2022Sell230,000$6.28$1,444,400.00View SEC Filing Icon  
3/11/2022Sell100,000$6.95$695,000.00View SEC Filing Icon  
3/7/2022Sell300,000$7.30$2,190,000.00View SEC Filing Icon  
2/22/2022Sell100,000$10.22$1,022,000.00View SEC Filing Icon  
1/31/2022Sell19,858$11.73$232,934.34View SEC Filing Icon  
1/13/2022Sell87,000$14.33$1,246,710.00View SEC Filing Icon  
12/16/2021Sell200$20.00$4,000.00View SEC Filing Icon  
12/13/2021Sell100$20.02$2,002.00View SEC Filing Icon  
12/9/2021Sell1,086$20.01$21,730.86View SEC Filing Icon  
12/7/2021Sell3,125$20.51$64,093.75View SEC Filing Icon  
See Full Table

Christopher Gibson Buying and Selling Activity at Recursion Pharmaceuticals

This chart shows Christopher Gibson's buying and selling at Recursion Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Recursion Pharmaceuticals Company Overview

Recursion Pharmaceuticals logo
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Read More

Today's Range

Now: $12.96
Low: $11.82
High: $13.06

50 Day Range

MA: $8.38
Low: $5.80
High: $12.04

2 Week Range

Now: $12.96
Low: $4.92
High: $29.40

Volume

1,352,909 shs

Average Volume

1,089,523 shs

Market Capitalization

$2.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
WARNING: Do You Invest with these Banks
Take a close look at these investment banks. Because if you own stocks with any of these brokerages...

This new political development WILL affect you.

If you invest with any of these brokerage firms, click here to see how to protect your portfolio from this new conflict.
>>>